...for the product (see BioCentury, Oct. 29). Ferring gained MVDS through its 2011 acquisition of Cytokine PharmaSciences Inc....

...product was submitted in the EU. Ferring gained the product through its 2011 acquisition of Cytokine PharmaSciences Inc....

...is a sustained release vaginal insert delivery a synthetic prostaglandin E2. Terms were not disclosed. Cytokine PharmaSciences Inc....

...vaginal insert were well tolerated. The most common adverse event was non-reassuring fetal heart rate. Cytokine PharmaSciences Inc....

...of a eukaryotic translation initiation factor 5A small interfering RNA in preclinical development for diabetes. Cytokine PharmaSciences Inc....
...Osherovich, L. SciBX 3 (23); doi:10.1038/scibx.2010.692 Published online June 10, 2010 Companies and Institutions Mentioned Cytokine PharmaSciences Inc....

...oral CPSI-2364 were well tolerated with no serious adverse events. The MTD was not reached. Cytokine PharmaSciences Inc....

...company began a dose-escalation Phase I trial to evaluate oral CPSI-2364 in 36 healthy volunteers. Cytokine PharmaSciences Inc....

...inhibition and the TLR blockade," said Vidal de la Cruz, VP of business development at Cytokine PharmaSciences Inc....
...and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cytokine PharmaSciences Inc....

...steps include determining the mechanism of neuroprotection and studies in additional mouse models of AD. Cytokine PharmaSciences Inc.'s...
...Phase I trial as an adjunct to IL-2 in cancer. Patent application filed; licensed to Cytokine PharmaSciences...

...2006 by Omar Haffar, Antoun Nabhan and David Jobes University collaborators: Stanford University Corporate partners: Cytokine PharmaSciences Inc....